Eli Lilly (LLY) Confirms Guidance for 2017, CEO Meets With Trump - TheStreet

Eli Lilly Confirms Guidance for 2017, CEO Meets With Trump

Eli Lilly reaffirms its 2017 guidance after reporting higher sales and earnings in its latest quarter.
Author:
Publish date:

Eli Lilly (LLY) - Get Report reported higher earnings and sales for the latest quarter and reaffirmed its financial guidance for 2017. For the fourth quarter, Lilly reported an adjusted profit of 95 cents a share, up 22%. Lilly's revenue increased 7% and was better than analysts' forecasts. For 2017, Lilly is forecasting adjusted earnings in the range of $4.05 to $4.15 a share, with revenue ranging between $21.8 billoin and $22.3 billion. Lilly's CEO David Ricks was among the pharmaceutical industry executives meeting with President Trump Tuesday morning, where Trump said he wanted to see lower drug prices.